Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
1. (r)-2-(7-((4-cyclo-pentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydro-cyclopenta(b)indol-3-yl)acetic Acid)
1. 1206123-37-6
2. Apd334
3. Apd-334
4. Etrasimod [usan]
5. 6wh8495mmh
6. Apd-334(free Acid)
7. Chembl3358920
8. Etrasimod (usan)
9. 1206123-37-6 (free Base)
10. (r)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
11. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl) Acetic Acid
12. 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic Acid
13. Etrasimod(apd334)
14. Etrasimod [inn]
15. Etrasimod [who-dd]
16. Unii-6wh8495mmh
17. Apd334apd334
18. Gtpl9331
19. Schembl1919311
20. Bcp19558
21. Ex-a1633
22. Bdbm50041691
23. Akos032944972
24. Zinc117522788
25. Apd334-003
26. Compound 4 [pmid: 25516790]
27. Cs-6181
28. Db14766
29. Ac-35444
30. Hy-12789
31. D10930
32. F10118
33. Q27265630
34. ((3r)-7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid
35. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
36. Cyclopent(b)indole-3-acetic Acid, 7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydro-, (3r)-
| Molecular Weight | 457.5 g/mol |
|---|---|
| Molecular Formula | C26H26F3NO3 |
| XLogP3 | 6.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 457.18647818 g/mol |
| Monoisotopic Mass | 457.18647818 g/mol |
| Topological Polar Surface Area | 62.3 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 695 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
A Etrasimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etrasimod, including repackagers and relabelers. The FDA regulates Etrasimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etrasimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Etrasimod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Etrasimod supplier is an individual or a company that provides Etrasimod active pharmaceutical ingredient (API) or Etrasimod finished formulations upon request. The Etrasimod suppliers may include Etrasimod API manufacturers, exporters, distributors and traders.
click here to find a list of Etrasimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Etrasimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etrasimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etrasimod GMP manufacturer or Etrasimod GMP API supplier for your needs.
A Etrasimod CoA (Certificate of Analysis) is a formal document that attests to Etrasimod's compliance with Etrasimod specifications and serves as a tool for batch-level quality control.
Etrasimod CoA mostly includes findings from lab analyses of a specific batch. For each Etrasimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etrasimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Etrasimod EP), Etrasimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etrasimod USP).
LOOKING FOR A SUPPLIER?
